In symptomatic peripheral artery disease with T2D, semaglutide increased maximum walking distance at 1 y

Matthew Ades; Sonia S. Anand

doi:10.7326/annals-25-03196-jc

September 1, 2025Annals of Internal Medicine

In symptomatic peripheral artery disease with T2D, semaglutide increased maximum walking distance at 1 y

View at Publisher

Ask AI

Bookmark

Share

Key Points

Semaglutide improved maximum walking distance in patients with symptomatic peripheral artery disease.
Participants showed an increase of walking distance after one year of treatment with semaglutide.
Assessment of walking ability was conducted in patients diagnosed with type 2 diabetes and peripheral artery disease.
These findings suggest that semaglutide could be an important therapy for enhancing mobility in this population.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Observational analysis showed semaglutide increased maximum walking distance in patients with T2D, indicating its potential benefits for peripheral artery disease.

Abstract

GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text] Endocrinology: [Formula: see text].

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ades et al. (2025) studied this question.

synapsesocial.com/papers/68bb4d206d6d5674bcd00f38 https://doi.org/10.7326/annals-25-03196-jc

View at Publisher

Ask AI

Bookmark

Share

In symptomatic peripheral artery disease with T2D, semaglutide increased maximum walking distance at 1 y

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

In symptomatic peripheral artery disease with T2D, semaglutide increased maximum walking distance at 1 y

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading